EVP, CHIEF MEDICAL OFFICER
Dr. Lee Scott Golden, M.D. (also known as Lee Golden) is Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (PTCT), a role he has held since April 2023, following positions as Chief Medical Officer (Jan 2022–Apr 2023) and SVP, Head of Global Clinical Development (May 2020–Jan 2022).[[1]](https://www.ptcbio.com/team/leadership/lee-golden/)[[2]](https://fintool.com/app/research/companies/PTCT/people/lee-golden)[[3]](https://www.quiverquant.com/news/Cadrenal+Therapeutics,+Inc.+Appoints+Dr.+Lee+Scott+Golden+to+Board+of+Directors) In this capacity, he leads global clinical development across PTC’s rare disease pipeline, contributing to key achievements such as FDA approval for Kebilidi, NDA submissions for sepiapterin (PKU), ataluren (nmDMD), and vatiquinone (FA), and on-time execution of PTC518 Phase 2 with interim results.[[2]](https://fintool.com/app/research/companies/PTCT/people/lee-golden)
Dr. Golden brings over 25 years of biopharmaceutical experience, with prior roles as Chief Medical Officer at Espero BioPharma (Oct 2018–May 2020, focusing on thrombosis and cardiac rhythm control) and Gemphire Therapeutics (Oct 2016–Sep 2018, cardiometabolic disorders), alongside senior positions at Pfizer, Actelion, Elan, Eisai, and Mesoblast.[[1]](https://www.ptcbio.com/team/leadership/lee-golden/)[[2]](https://fintool.com/app/research/companies/PTCT/people/lee-golden)[[3]](https://www.quiverquant.com/news/Cadrenal+Therapeutics,+Inc.+Appoints+Dr.+Lee+Scott+Golden+to+Board+of+Directors) He currently serves as an independent director on the Board of Cadrenal Therapeutics, Inc., and Chairman of the Advisory Board for Coagulation Sciences LLC.[[3]](https://www.quiverquant.com/news/Cadrenal+Therapeutics,+Inc.+Appoints+Dr.+Lee+Scott+Golden+to+Board+of+Directors)[[4]](https://biotuesdays.com/2025/12/01/cadrenal-appoints-dr-lee-golden-to-bod/) A graduate of New York University School of Medicine (M.D., Internal Medicine residency), he holds a B.S. from the University of Michigan, with fellowships in Cardiology (University of Miami) and Interventional Cardiology (George Washington University Hospital).[[1]](https://www.ptcbio.com/team/leadership/lee-golden/)[[2]](https://fintool.com/app/research/companies/PTCT/people/lee-golden)[[3]](https://www.quiverquant.com/news/Cadrenal+Therapeutics,+Inc.+Appoints+Dr.+Lee+Scott+Golden+to+Board+of+Directors)
View full insider profile →
